Testing new antiviral treatments using cultured viruses.
Official title: TASK B26: COMPREHENSIVE VIRAL SCREENING PANEL.
Funded at University of Alabama at Birmingham · NIH-11307307 · Data updated 2026-11-12
This study is testing new antiviral medicines in the lab to see how well they work against viruses, which could help people with viral infections in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | December 16, 2024 |
| Project end | December 15, 2025 |
| Funding year | 2025 |
| Award (this year) | $22,103 |
| NIH project number | 75N93019D00016-0-759302500001-1 |
| Project ID | NIH-11307307 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with viral infections who may benefit from new antiviral treatments.
✕Less likely to help
Patients with non-viral infections or those who are not currently infected with a virus may not receive any benefit from this research.
What this research studies
This research focuses on evaluating potential antiviral agents through laboratory testing. It involves maintaining viral stocks and cell lines to grow viruses, which allows researchers to assess the effectiveness of various antiviral compounds. Patients may benefit from the development of new antiviral medications that could be more effective against viral infections. The research employs in vitro testing methods, meaning it is conducted in a controlled laboratory environment rather than in living organisms.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antiviral medications for patients.
How similar studies have gone: Other research has shown success in developing antiviral agents through similar in vitro testing approaches.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: James, Scott — University of Alabama at Birmingham
- Study coordinator: James, Scott
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Exploring how Down syndrome affects optic nerve health in kids
A study using a mouse model to understand why optic nerve problems are common in children with Down syndrome and how to prevent them.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.